<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories

In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Ettore Capoluongo [verfasserIn] Nicla La Verde [verfasserIn] Massimo Barberis [verfasserIn] Maria Angela Bella [verfasserIn] Fiamma Buttitta [verfasserIn] Paola Carrera [verfasserIn] Nicoletta Colombo [verfasserIn] Laura Cortesi [verfasserIn] Maurizio Genuardi [verfasserIn] Massimo Gion [verfasserIn] Valentina Guarneri [verfasserIn] Domenica Lorusso [verfasserIn] Antonio Marchetti [verfasserIn] Paolo Marchetti [verfasserIn] Nicola Normanno [verfasserIn] Barbara Pasini [verfasserIn] Matilde Pensabene [verfasserIn] Sandro Pignata [verfasserIn] Paolo Radice [verfasserIn] Enrico Ricevuto [verfasserIn] Anna Sapino [verfasserIn] Pierosandro Tagliaferri [verfasserIn] Pierfrancesco Tassone [verfasserIn] Chiara Trevisiol [verfasserIn] Mauro Truini [verfasserIn] Liliana Varesco [verfasserIn] Antonio Russo [verfasserIn] Stefania Gori [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2019

Schlagwörter:	ngs somatic brca parp-1i

Übergeordnetes Werk:	In: Diagnostics - MDPI AG, 2012, 9(2019), 4, p 146
Übergeordnetes Werk:	volume:9 ; year:2019 ; number:4, p 146

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.3390/diagnostics9040146

Katalog-ID:	DOAJ086653156

Internformat


LEADER	01000naa a22002652 4500
001	DOAJ086653156
003	DE-627
005	20230311052523.0
007	cr uuu---uuuuu
008	230311s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.3390/diagnostics9040146 \|2 doi
035			\|a (DE-627)DOAJ086653156
035			\|a (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a R5-920
100	0		\|a Ettore Capoluongo \|e verfasserin \|4 aut
245	1	0	\|a <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.
650		4	\|a ngs
650		4	\|a <i<brca1/2</i< assays
650		4	\|a somatic brca
650		4	\|a parp-1i
653		0	\|a Medicine (General)
700	0		\|a Nicla La Verde \|e verfasserin \|4 aut
700	0		\|a Massimo Barberis \|e verfasserin \|4 aut
700	0		\|a Maria Angela Bella \|e verfasserin \|4 aut
700	0		\|a Fiamma Buttitta \|e verfasserin \|4 aut
700	0		\|a Paola Carrera \|e verfasserin \|4 aut
700	0		\|a Nicoletta Colombo \|e verfasserin \|4 aut
700	0		\|a Laura Cortesi \|e verfasserin \|4 aut
700	0		\|a Maurizio Genuardi \|e verfasserin \|4 aut
700	0		\|a Massimo Gion \|e verfasserin \|4 aut
700	0		\|a Valentina Guarneri \|e verfasserin \|4 aut
700	0		\|a Domenica Lorusso \|e verfasserin \|4 aut
700	0		\|a Antonio Marchetti \|e verfasserin \|4 aut
700	0		\|a Paolo Marchetti \|e verfasserin \|4 aut
700	0		\|a Nicola Normanno \|e verfasserin \|4 aut
700	0		\|a Barbara Pasini \|e verfasserin \|4 aut
700	0		\|a Matilde Pensabene \|e verfasserin \|4 aut
700	0		\|a Sandro Pignata \|e verfasserin \|4 aut
700	0		\|a Paolo Radice \|e verfasserin \|4 aut
700	0		\|a Enrico Ricevuto \|e verfasserin \|4 aut
700	0		\|a Anna Sapino \|e verfasserin \|4 aut
700	0		\|a Pierosandro Tagliaferri \|e verfasserin \|4 aut
700	0		\|a Pierfrancesco Tassone \|e verfasserin \|4 aut
700	0		\|a Chiara Trevisiol \|e verfasserin \|4 aut
700	0		\|a Mauro Truini \|e verfasserin \|4 aut
700	0		\|a Liliana Varesco \|e verfasserin \|4 aut
700	0		\|a Antonio Russo \|e verfasserin \|4 aut
700	0		\|a Stefania Gori \|e verfasserin \|4 aut
773	0	8	\|i In \|t Diagnostics \|d MDPI AG, 2012 \|g 9(2019), 4, p 146 \|w (DE-627)718627814 \|w (DE-600)2662336-5 \|x 20754418 \|7 nnns
773	1	8	\|g volume:9 \|g year:2019 \|g number:4, p 146
856	4	0	\|u https://doi.org/10.3390/diagnostics9040146 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/602ff62a14b84094a5b190129f3575ac \|z kostenfrei
856	4	0	\|u https://www.mdpi.com/2075-4418/9/4/146 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2075-4418 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 9 \|j 2019 \|e 4, p 146

Indexfelder

author_variant	e c ec n l v nlv m b mb m a b mab f b fb p c pc n c nc l c lc m g mg m g mg v g vg d l dl a m am p m pm n n nn b p bp m p mp s p sp p r pr e r er a s as p t pt p t pt c t ct m t mt l v lv a r ar s g sg
matchkey_str	article:20754418:2019----::bc1ioeuaasyooainacrainssretruhtladprmnsfnooynmlcl
hierarchy_sort_str	2019
callnumber-subject-code	R
publishDate	2019
allfields	10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146
spelling	10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146
allfields_unstemmed	10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146
allfieldsGer	10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146
allfieldsSound	10.3390/diagnostics9040146 doi (DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac DE-627 ger DE-627 rakwb eng R5-920 Ettore Capoluongo verfasserin aut <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput. ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General) Nicla La Verde verfasserin aut Massimo Barberis verfasserin aut Maria Angela Bella verfasserin aut Fiamma Buttitta verfasserin aut Paola Carrera verfasserin aut Nicoletta Colombo verfasserin aut Laura Cortesi verfasserin aut Maurizio Genuardi verfasserin aut Massimo Gion verfasserin aut Valentina Guarneri verfasserin aut Domenica Lorusso verfasserin aut Antonio Marchetti verfasserin aut Paolo Marchetti verfasserin aut Nicola Normanno verfasserin aut Barbara Pasini verfasserin aut Matilde Pensabene verfasserin aut Sandro Pignata verfasserin aut Paolo Radice verfasserin aut Enrico Ricevuto verfasserin aut Anna Sapino verfasserin aut Pierosandro Tagliaferri verfasserin aut Pierfrancesco Tassone verfasserin aut Chiara Trevisiol verfasserin aut Mauro Truini verfasserin aut Liliana Varesco verfasserin aut Antonio Russo verfasserin aut Stefania Gori verfasserin aut In Diagnostics MDPI AG, 2012 9(2019), 4, p 146 (DE-627)718627814 (DE-600)2662336-5 20754418 nnns volume:9 year:2019 number:4, p 146 https://doi.org/10.3390/diagnostics9040146 kostenfrei https://doaj.org/article/602ff62a14b84094a5b190129f3575ac kostenfrei https://www.mdpi.com/2075-4418/9/4/146 kostenfrei https://doaj.org/toc/2075-4418 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2019 4, p 146
language	English
source	In Diagnostics 9(2019), 4, p 146 volume:9 year:2019 number:4, p 146
sourceStr	In Diagnostics 9(2019), 4, p 146 volume:9 year:2019 number:4, p 146
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	ngs <i<brca1/2</i< assays somatic brca parp-1i Medicine (General)
isfreeaccess_bool	true
container_title	Diagnostics
authorswithroles_txt_mv	Ettore Capoluongo @@aut@@ Nicla La Verde @@aut@@ Massimo Barberis @@aut@@ Maria Angela Bella @@aut@@ Fiamma Buttitta @@aut@@ Paola Carrera @@aut@@ Nicoletta Colombo @@aut@@ Laura Cortesi @@aut@@ Maurizio Genuardi @@aut@@ Massimo Gion @@aut@@ Valentina Guarneri @@aut@@ Domenica Lorusso @@aut@@ Antonio Marchetti @@aut@@ Paolo Marchetti @@aut@@ Nicola Normanno @@aut@@ Barbara Pasini @@aut@@ Matilde Pensabene @@aut@@ Sandro Pignata @@aut@@ Paolo Radice @@aut@@ Enrico Ricevuto @@aut@@ Anna Sapino @@aut@@ Pierosandro Tagliaferri @@aut@@ Pierfrancesco Tassone @@aut@@ Chiara Trevisiol @@aut@@ Mauro Truini @@aut@@ Liliana Varesco @@aut@@ Antonio Russo @@aut@@ Stefania Gori @@aut@@
publishDateDaySort_date	2019-01-01T00:00:00Z
hierarchy_top_id	718627814
id	DOAJ086653156
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ086653156</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230311052523.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/diagnostics9040146</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ086653156</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ602ff62a14b84094a5b190129f3575ac</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ettore Capoluongo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a"><i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ngs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<brca1/2</i< assays</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">somatic brca</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parp-1i</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicla La Verde</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Barberis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Angela Bella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fiamma Buttitta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Carrera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicoletta Colombo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laura Cortesi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurizio Genuardi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Gion</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Domenica Lorusso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Marchetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Marchetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Normanno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barbara Pasini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matilde Pensabene</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandro Pignata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Radice</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Enrico Ricevuto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Sapino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierosandro Tagliaferri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierfrancesco Tassone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Trevisiol</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mauro Truini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liliana Varesco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefania Gori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diagnostics</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">9(2019), 4, p 146</subfield><subfield code="w">(DE-627)718627814</subfield><subfield code="w">(DE-600)2662336-5</subfield><subfield code="x">20754418</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4, p 146</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/diagnostics9040146</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/602ff62a14b84094a5b190129f3575ac</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2075-4418/9/4/146</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2075-4418</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2019</subfield><subfield code="e">4, p 146</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Ettore Capoluongo
spellingShingle	Ettore Capoluongo misc R5-920 misc ngs misc <i<brca1/2</i< assays misc somatic brca misc parp-1i misc Medicine (General) <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
authorStr	Ettore Capoluongo
ppnlink_with_tag_str_mv	@@773@@(DE-627)718627814
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	R5-920
illustrated	Not Illustrated
issn	20754418
topic_title	R5-920 <i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories ngs <i<brca1/2</i< assays somatic brca parp-1i
topic	misc R5-920 misc ngs misc <i<brca1/2</i< assays misc somatic brca misc parp-1i misc Medicine (General)
topic_unstemmed	misc R5-920 misc ngs misc <i<brca1/2</i< assays misc somatic brca misc parp-1i misc Medicine (General)
topic_browse	misc R5-920 misc ngs misc <i<brca1/2</i< assays misc somatic brca misc parp-1i misc Medicine (General)
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Diagnostics
hierarchy_parent_id	718627814
hierarchy_top_title	Diagnostics
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)718627814 (DE-600)2662336-5
title	<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
ctrlnum	(DE-627)DOAJ086653156 (DE-599)DOAJ602ff62a14b84094a5b190129f3575ac
title_full	<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
author_sort	Ettore Capoluongo
journal	Diagnostics
journalStr	Diagnostics
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2019
contenttype_str_mv	txt
author_browse	Ettore Capoluongo Nicla La Verde Massimo Barberis Maria Angela Bella Fiamma Buttitta Paola Carrera Nicoletta Colombo Laura Cortesi Maurizio Genuardi Massimo Gion Valentina Guarneri Domenica Lorusso Antonio Marchetti Paolo Marchetti Nicola Normanno Barbara Pasini Matilde Pensabene Sandro Pignata Paolo Radice Enrico Ricevuto Anna Sapino Pierosandro Tagliaferri Pierfrancesco Tassone Chiara Trevisiol Mauro Truini Liliana Varesco Antonio Russo Stefania Gori
container_volume	9
class	R5-920
format_se	Elektronische Aufsätze
author-letter	Ettore Capoluongo
doi_str_mv	10.3390/diagnostics9040146
author2-role	verfasserin
title_sort	<i<brca1/2</i< molecular assay for ovarian cancer patients: a survey through italian departments of oncology and molecular and genomic diagnostic laboratories
callnumber	R5-920
title_auth	<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
abstract	In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.
abstractGer	In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.
abstract_unstemmed	In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	4, p 146
title_short	<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories
url	https://doi.org/10.3390/diagnostics9040146 https://doaj.org/article/602ff62a14b84094a5b190129f3575ac https://www.mdpi.com/2075-4418/9/4/146 https://doaj.org/toc/2075-4418
remote_bool	true
author2	Nicla La Verde Massimo Barberis Maria Angela Bella Fiamma Buttitta Paola Carrera Nicoletta Colombo Laura Cortesi Maurizio Genuardi Massimo Gion Valentina Guarneri Domenica Lorusso Antonio Marchetti Paolo Marchetti Nicola Normanno Barbara Pasini Matilde Pensabene Sandro Pignata Paolo Radice Enrico Ricevuto Anna Sapino Pierosandro Tagliaferri Pierfrancesco Tassone Chiara Trevisiol Mauro Truini Liliana Varesco Antonio Russo Stefania Gori
author2Str	Nicla La Verde Massimo Barberis Maria Angela Bella Fiamma Buttitta Paola Carrera Nicoletta Colombo Laura Cortesi Maurizio Genuardi Massimo Gion Valentina Guarneri Domenica Lorusso Antonio Marchetti Paolo Marchetti Nicola Normanno Barbara Pasini Matilde Pensabene Sandro Pignata Paolo Radice Enrico Ricevuto Anna Sapino Pierosandro Tagliaferri Pierfrancesco Tassone Chiara Trevisiol Mauro Truini Liliana Varesco Antonio Russo Stefania Gori
ppnlink	718627814
callnumber-subject	R - General Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.3390/diagnostics9040146
callnumber-a	R5-920
up_date	2024-07-03T21:59:15.865Z
_version_	1803596811079778304
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ086653156</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230311052523.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230311s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/diagnostics9040146</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ086653156</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ602ff62a14b84094a5b190129f3575ac</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">R5-920</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Ettore Capoluongo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a"><i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In Italy, 5200 new ovarian cancers were diagnosed in 2018, highlighting an increasing need to test women for <i<BRCA1/2</i<. The number of labs offering this test is continuously increasing. The aim of this study was to show the results coming from the intersociety survey coordinated by four different Clinical and Laboratory Italian Scientific Societies (AIOM, SIAPEC-IAP, SIBIOC, and SIGU). A multidisciplinary team belonging to the four scientific societies drew up two different questionnaires: One was targeted toward all Italian Departments of Medical Oncology, and the second toward laboratories of clinical molecular biology. This survey was implemented from September 2017 to March 2018. Seventy-seven out of 305 (25%) Departments of Medical Oncology filled our survey form. Indeed, 59 molecular laboratories were invited. A total of 41 laboratories (70%) filled in the questionnaire. From 2014 to 2017, 16 new molecular laboratories were activated. A total of 12,559 tests were performed in the year 2016, with a mean of 339 tests and a median of 254 tests per laboratory, showing a glimpse of an extreme low number of tests performed per year by some laboratories. In terms of the type and number of professionals involved in the pre- and post-test counseling, results among the onco-genetic team were heterogeneous. Our data show that the number of laboratories providing <i<BRCA1/2</i< germline assays is significantly increased with further implementation of the somatic test coming soon. The harmonization of the complete laboratory diagnostic path should be encouraged, particularly in order to reduce the gap between laboratories with high and low throughput.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">ngs</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a"><i<brca1/2</i< assays</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">somatic brca</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">parp-1i</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine (General)</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicla La Verde</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Barberis</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maria Angela Bella</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Fiamma Buttitta</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paola Carrera</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicoletta Colombo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Laura Cortesi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Maurizio Genuardi</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Massimo Gion</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Valentina Guarneri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Domenica Lorusso</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Marchetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Marchetti</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Nicola Normanno</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Barbara Pasini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Matilde Pensabene</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sandro Pignata</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Paolo Radice</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Enrico Ricevuto</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Anna Sapino</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierosandro Tagliaferri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pierfrancesco Tassone</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Chiara Trevisiol</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Mauro Truini</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Liliana Varesco</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Antonio Russo</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Stefania Gori</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Diagnostics</subfield><subfield code="d">MDPI AG, 2012</subfield><subfield code="g">9(2019), 4, p 146</subfield><subfield code="w">(DE-627)718627814</subfield><subfield code="w">(DE-600)2662336-5</subfield><subfield code="x">20754418</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:4, p 146</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/diagnostics9040146</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/602ff62a14b84094a5b190129f3575ac</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/2075-4418/9/4/146</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2075-4418</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2019</subfield><subfield code="e">4, p 146</subfield></datafield></record></collection>
score	7.3974285

Nicht das Richtige dabei?

Schreiben Sie uns!

<i<BRCA1/2</i< Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?